uniQure stock falls 10.38 percent as cash reaches USD 810.3 million
Published on 09/25/2026 at 07:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
uniQure stock fell 10.38 percent to USD 38.32 on Nasdaq on September 24, 2026, leaving the biotechnology company 46.41 percent below its 52-week high of USD 71.50. The move came as investors weighed the regulatory path for AMT-130 and the company's continuing cash consumption.
AMT-130 advances toward review
In a September 2026 report, Yahoo Finance said uniQure had submitted a Biologics License Application for AMT-130 in Huntington's disease and requested priority review.
The application relies on three-year Phase I/II data compared with a propensity-score-matched external control. If priority review is granted, the review cycle would be six months after the FDA completes its filing review, while the agency still has to decide whether to accept the application.
Revenue rises while costs diverge
For Q2 2026, revenue increased to USD 5.8 million from USD 5.3 million in the comparable quarter of 2025, a 9.43 percent gain, according to the Yahoo Finance transcript.
Research and development expense declined to USD 34.0 million from USD 35.4 million, while selling, general, and administrative expense rose to USD 17.4 million from USD 13.5 million. The contrast shows why the regulatory timetable matters more than revenue growth alone for this development-stage company.
Cash, cash equivalents, and investment securities totaled USD 810.3 million on June 30, 2026, compared with USD 622.5 million on December 31, 2025. Management said the resources are expected to fund operations into 2030, according to the same Q2 2026 earnings-call transcript.
Stock remains below yearly high
uniQure had a market capitalization of USD 2,658,120,448 as of September 24, 2026. The USD 38.32 price was inside the 52-week range of USD 8.73 to USD 71.50, but its 46.41 percent discount to the high underlines the distance between regulatory potential and market confidence.
Nasdaq price snapshot
uniQure stock stood at USD 38.32 on Nasdaq on September 24, 2026, down USD 4.44 or 10.38 percent from the prior close. The closing market value places the company at USD 2,658,120,448 in market capitalization.
uniQure market snapshot
- Company: uniQure N.V.
- Ticker: QURE
- Trading venue: Nasdaq
- Price as of September 24, 2026: USD 38.32
- Market capitalization: USD 2,658,120,448 as of September 24, 2026
- 52-week range: USD 8.73-71.50
- Sector / Industry: Healthcare / Biotechnology
